WuXi PharmaTech Completes $3.3 Billion Going-Private Transaction

On December 10, 2015, WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the U.S., announced that it has completed its merger with WuXi Merger Limited, a special-purpose vehicle controlled by a buyer group consisting of certain founders and executive officers of WuXi PharmaTech and affiliates of or funds managed or advised by Boyu Capital, Temasek, Ally Bridge Group, Ping An Insurance, Hillhouse Capital, Yinfu Capital, SPDB International, Legend Capital, Sequoia Capital, and Yunfeng Capital. As a result of the merger, the buyer group acquired the company in a cash transaction valued at approximately $3.3 billion—the largest going-private transaction of a U.S.-listed China-based company to date. Wilson Sonsini Goodrich & Rosati acted as U.S. and Hong Kong legal counsel to the founders and as lead counsel to the buyer group in the transaction.

The WSGR team that advised the founders and buyer group in the transaction included:

Weiheng Chen, Partner
Zhan Chen, Partner
Jie Zhu, Partner-Elect
Zuolong Wu, Associate
Xuchao Dong, Associate
Ke Li, Associate

Rodney Strickland, Partner

John Fore, Partner
Kathleen Rothman, Partner
Dana Hall, Associate

Don Vieira, Partner
Paul McGeown, Partner
Paul Jin, Partner
Christopher Williams, Associate
Yichen Wu, Associate

Employee Benefits & Compensation
Scott McCall, Partner
Michelle Wallin, Partner
Sriram Krishnamurthy, Partner-Elect
Lucericia Messiah, Associate
Christa Sanchez, Associate

Employment Law
Rebecca Stuart, Associate

Jonathan Zhu, Partner
Myra Sutanto Shen, Associate

Intellectual Property
Karen Wong, Partner

For more information, please see the WuXi PharmaTech's press release.